Psychedelic Stocks Hit With Bad Trip After FDA Advisers Reject MDMA Treatment For PTSD Psychedelic stocks were battered in premarket trading after a panel of experts advising the Food and Drug Administration rejected the approval of MDMA for post-traumatic (PTSD) stress disorder. There were two votes – one for MDMA’s efficacy and another for safety, by the FDA’s Psychopharmacologic Drugs Advisory […]
The post is from Mad Mad News